Log In
BCIQ
Print this Print this
 

Caerulomycin A

  Manage Alerts
Collapse Summary General Information
Company Institute of Microbial Technology
DescriptionBipyridyl immunosuppressant
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationOrgan transplant rejection
Indication DetailsPrevent organ transplant rejection
Regulatory Designation
PartnerNostrum Pharmaceuticals LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/02/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today